Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder

Trial Profile

Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder

Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Atomoxetine (Primary) ; Methylphenidate (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 08 Sep 2015 Status changed from recruiting to completed as per data presented in the European Neuropsychopharmacology.
    • 08 Sep 2015 Results published in the European Neuropsychopharmacology.
    • 09 Jul 2012 Additional lead trial centre identified as reported by
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top